Pacific Eagle Asset Management
1
150M
1
0.03
- Areas of investment
Summary
Pacific Eagle Asset Management appeared to be the VC, which was created in 1992. The main office of represented VC is situated in the San Ramon. The fund was located in North America if to be more exact in United States.
The usual cause for the fund is to invest in rounds with 6 partakers. Despite the Pacific Eagle Asset Management, startups are often financed by Carrie Cox. The meaningful sponsors for the fund in investment in the same round are Reignwood Group, Gavril Yushvaev, Brady Dougan. In the next rounds fund is usually obtained by California Institute for Regenerative Medicine.
Besides them, we counted 6 critical employees of this fund in our database.
The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2015. The common things for fund are deals in the range of more than 100 millions dollars.
Among the most successful fund investment fields, there are Biotechnology, Medical Device. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Humacyte
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.03
- Investments by industry
- Biotechnology (1)
- Medical Device (1)
- Medical (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2015
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Avg. valuation at time of investment
- 640M
- Group Appearance index
- 1.00
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Humacyte | 20 Oct 2015 | Biotechnology, Medical Device, Medical | Early Stage Venture | 150M | United States, North Carolina |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.